

February 9, 2017

Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2017

SAN DIEGO, Feb. 9, 2017 /PRNewswire/ -- <u>Arena Pharmaceuticals, Inc.</u> (NASDAQ: ARNA) today announced that Dr. Scott Lee and Professor Tanja Kühbacher will present data on etrasimod (APD334) at the <u>12th Congress of European Crohn's and Colitis Organisation</u> (ECCO) - Inflammatory Bowel Diseases 2017 on Friday, February 17. The conference is taking place February 15-18 at the CCIB Barcelona in Barcelona, Spain. The <u>data</u> are available in <u>the Journal of Crohn's and Colitis</u>, Volume 11, Issue Supplement 1.

The following abstracts will be presented:

Title: Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P

receptor modulator, after dose escalation in healthy volunteers

Session Type: Poster Presentation Poster Presentation Number: P369 Date: February 17 at 12:30pm CET Location: Poster Exhibition Area

Title: Immunomodulatory effects of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator

Presenter: Scott Lee

Session Type: Digital Oral Presentation Digital Oral Presentation Number: DOP077

Date: February 17 at 5:44pm CET Location: Room 111 - Level 1

Title: Pharmacology and safety of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator

Presenter: Tanja Kühbacher

Session Type: Digital Oral Presentation Digital Oral Presentation Number: DOP078

Date: February 17 at 5:50pm CET Location: Room 111 - Level 1

About Arena Pharmaceuticals

We are a biopharmaceutical company focused on developing novel, small molecule drugs across a range of therapeutic areas. We have three primary proprietary investigational <u>clinical programs</u>: <u>etrasimod</u> (APD334) in Phase 2 evaluation for ulcerative colitis, <u>APD371</u> entering Phase 2 evaluation for the treatment of pain associated with Crohn's disease, and <u>ralinepag</u> (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH). Additionally, we have collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences Ltd. (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).

Our US operations are located in San Diego, California. Our primary clinical operations are located in Zug, Switzerland, and our commercial manufacturing for BELVIQ is located in Zofingen, Switzerland.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the upcoming presentations; and Arena's focus, primary programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc. Kevin R. Lind, Chief Financial Officer



To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-three-upcoming-presentations-at-the-12th-congress-of-european-crohns-and-colitis-organisation---inflammatory-bowel-diseases-2017-300404708.html

SOURCE Arena Pharmaceuticals, Inc.

News Provided by Acquire Media